M.D. - CEO
Current board member and advisor for several biotech companies, Gilles Avenard is Medical Doctor and was the co-founder and COO of BioAlliance Pharma SA – ONXEO (NYSE EURONEXT) until 2010. He was notably involved in the development of several innovative medicines through to their official registration on both European and North-American territories. Before that, he worked as Project Director for Hoechst Marion Roussel (Sanofi) and was Medical Director of Bio-Transfusion (LFB).
After an extensive professional experience at a court-appointed representative’s office in Paris, Nacera Brouttelande joined Acticor Biotech in June 2018 where she works as office manager notably dealing with the company’s administrative, legal and accounting follow-up.
Andrea Comenducci, MD, Medical Director at Acticor Biotech. Educated as a General Practitioner, Andrea has a 25-year experience in the pharmaceutical industry. He assumed various functions from International Project leader and Senior Medical Advisor to Medical Director in medium and large companies. His preferred therapeutic area is the cardiovascular field in which he has vast experience in coronary diseases, high blood pressure, heart failure, atherosclerosis acquired in large worldwide clinical trials such as the GUSTO V-TIMI 14 study, STABILITY and SOLID-TIMI 52 studies. In November 2018, Andrea joined Acticor Biotech with the role of Medical Director in order to take up new exciting challenges in acute ischemic stroke and pulmonary embolism.
MBA – CFO
CEO and Founder of Agile Capital Markets; Advisor of several biotech & medtech companies (among which EOS imaging, Cellnovo, PKvitality), Eric raised over 200M€ in public and private fund raising. He was previously CFO of Mauna Kea Technologies (Euronext®: MKEA), Hybrigenics (Euronext®: ALHYG) and Teva Pharmaceuticals France (NASDAQ®: TLV). He led 2 IPO on Euronext® raising 62M€. He was also Head of Hybrigenics Business Services and Head of Operations (R&D and Production) at Mauna Kea Technologies.
Ph.D. – CMC Adviser
Founder of 3Biotech, Olivier Favre-Bulle specializes in Pharmaceutical Development of Large and Small Molecules. After a Ph.D in Bioengineering, he started his career as project manager in Biological Drugs development at Rhône-Poulenc. He was site manager and European Head of Drug Development for Covance, and he also directed the NNE Pharmaplan France, a subsidiary of Novo Nordisk.
With a professional bachelor’s degree in pharmaceutical industries, focusing on biotechnology. P. Ferlan started her career in Sanofi’s R&D laboratories. She works on analytical methods development, stability studies and functional characterization of ACT017.
Financial and Administrative Manager
With a Master’s degree in Accounting and Finance, Aymeric was an Audit Manager at Grant Thornton for 7 years. He worked on listed and non-listed companies and specialized in the Biotech industry. He joined Acticor Biotech in January 2019 as Administrative and Finance Manager.
Head of Regulatory Affairs and Quality
PharmD., after a Master’s in International Drug Development and Registration, Laurie Jullien started at Genentech (USA) in Product Drug Development and was appointed Regulatory Affairs Labelling Manager at Roche (UK). She joined Acticor Biotech in 2016 and is in charge of regulatory and quality strategy.
Ph.D. – Scientific Director
Sophie has over 20 years’ experience in start-ups and mid-size companies within the biotechnology areas. She has a strong expertise in oncology, immunology and virology. Sophie has managed a number of innovative R&D projects from the proof-of-concept to early clinical development. In her previous positions, Sophie was Vice-President Research and Early Clinical Development at PEP-Therapy, responsible for the development of peptide drug candidates and their biomarkers up to clinical trials. She was responsible for nonclinical R&D activities at InnaVirVax, developing innovative immune-based treatments for infectious diseases. She was Head of translational programs in oncology at Gustave Roussy Cancer Center, where she coordinated research programs and implemented innovative technology platforms dedicated to translational research. During her carrier, Sophie held various positions, at INSERM, CEA, Centre d’Immunologie Pierre Fabre, VIRalliance and Stallergenes. Sophie holds a PhD in immunology from Paris VII Denis Diderot university. She is (co-)author of about 20 scientific publications and co-inventor of 9 patents.
Head of Pharmaceutical & Non-Clinical Development
Master degree of Biotechnology Engineering with a focus on R&D and Health, Kristell Lebozec has a 2 years experience in academic laboratories (Institut Gustave Roussy and Centre de Recherche des Cordeliers) and in the industry (DNA Therapeutics and I-Stem). She joined Acticor Biotech in 2015 and was in charge of selecting ACT017 expression system and of the functional characterization of product. She is now managing the pharmaceutical and non-clinical development.
M.D. - CMO
Dr Plétan is an expert in clinical development within the pharmaceutical industry. He previously held leadership positions at Roche, Pfizer, Sanofi and Pierre Fabre. Before joining Acticor Biotech, Dr Plétan served as head of the Medical Division and was a board member of the Foundation at Roche France and member of the Global Medical Affairs Committee at Hoffman La Roche Ltd (Switzerland). Prior to these activities, he was also vice-president, head of Medical and Scientific Division and board member of the Foundation at Pfizer.
PharmD. – Master in Quality Assurance – Pharmaceutical Products.
Victoria Rutman has 3 years of hands-on experience in the pharmaceutical industry. Primarily, at Orphan Europe, she worked in the Quality Assurance Department before being promoted as a Packaging and Equipment project manager.
She is in charge of the Quality system management at Acticor.